153 related articles for article (PubMed ID: 7682355)
1. Neurotoxicity of FK 506 in liver transplant recipients.
Frank B; Perdrizet GA; White HM; Marsh JW; Lemann W; Woodle ES
Transplant Proc; 1993 Apr; 25(2):1887-8. PubMed ID: 7682355
[No Abstract] [Full Text] [Related]
2. The superior immunosuppressant according to diagnosis: FK 506 or cyclosporine A.
Mueller AR; Platz KP; Blumhardt G; Bechstein WO; Steinmüller T; Christe W; Hopf U; Lobeck H; Neuhaus P
Transplant Proc; 1995 Feb; 27(1):1117-20. PubMed ID: 7533359
[No Abstract] [Full Text] [Related]
3. Similar clinical presentation of neurotoxicity following FK 506 and cyclosporine in a liver transplant recipient.
Freise CE; Rowley H; Lake J; Hebert M; Ascher NL; Roberts JP
Transplant Proc; 1991 Dec; 23(6):3173-4. PubMed ID: 1721397
[No Abstract] [Full Text] [Related]
4. Increased rejection after liver transplantation in FK 506-treated patients is associated with viral hepatitis C disease.
Mueller AR; Platz KP; Bechstein WO; Blumhardt G; Lobeck H; Hop U; Neuhaus P
Transplant Proc; 1994 Dec; 26(6):3637-9. PubMed ID: 7527984
[No Abstract] [Full Text] [Related]
5. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.
Yu S; He X; Yang L; Ma Y; Zhu X; Ju W; Huang J
Exp Clin Transplant; 2008 Jun; 6(2):113-7. PubMed ID: 18816237
[TBL] [Abstract][Full Text] [Related]
6. Comparison of FK 506- and cyclosporine-based immunosuppression: FK 506 therapy significantly reduces the incidence of acute, steroid-resistant, refractory, and chronic rejection whilst possessing a comparable safety profile. European FK 506 Multicenter Liver Study Group.
Bismuth H
Transplant Proc; 1995 Feb; 27(1):45-9. PubMed ID: 7533415
[No Abstract] [Full Text] [Related]
7. [Comparison between tacrolimus (FK 506) and cyclosporin in immunosuppressive therapy after liver transplantation].
Arnold JC; Theilmann L
Z Gastroenterol; 1995 Oct; 33(10):624-5. PubMed ID: 7502559
[No Abstract] [Full Text] [Related]
8. Neurological disorders in liver and kidney transplant recipients.
Christe W
Transplant Proc; 1994 Dec; 26(6):3175-6. PubMed ID: 7527953
[No Abstract] [Full Text] [Related]
9. Recurrent rejection following FK 506 rescue therapy for acute hepatic allograft rejection.
Woodle ES; So S; Jendrisak MD; Perdrizet GA; White HM; Marsh JW
Transplant Proc; 1993 Apr; 25(2):1988-9. PubMed ID: 7682358
[No Abstract] [Full Text] [Related]
10. Nephrotoxicity of FK 506 and cyclosporine when used as primary immunosuppression in liver transplant recipients.
Porayko MK; Textor SC; Krom RA; Hay JE; Gores GJ; Wahlstrom HE; Sanchez-Urdazpal L; Richards T; Crotty P; Beaver S
Transplant Proc; 1993 Feb; 25(1 Pt 1):665-8. PubMed ID: 7679835
[No Abstract] [Full Text] [Related]
11. FK 506 rescue therapy: the rapidity of rejection reversal is related to the subsequent development of CMV disease.
Woodle ES; Perdrizet GA; So S; Jendrisak MD; White HM; Marsh JW
Transplant Proc; 1993 Apr; 25(2):1992-3. PubMed ID: 7682360
[No Abstract] [Full Text] [Related]
12. Clinical evaluation of trough levels and area under the curve in cyclosporine- and FK 506-treated kidney transplant recipients.
Takahara S; Kokado Y; Kameoka H; Takano Y; Moutabarrik A; Jiang H; Ishibashi M; Okuyama A; Nishi Y; Chiba N
Transplant Proc; 1994 Oct; 26(5):2802-6. PubMed ID: 7524219
[No Abstract] [Full Text] [Related]
13. A randomized, prospective, pharmacoeconomic trial of neoral 2-hour postdose concentration monitoring versus tacrolimus trough concentration monitoring in de novo liver transplant recipients.
Shenoy S; Hardinger KL; Crippin J; Korenblat K; Lisker-Melman M; Lowell JA; Chapman W
Liver Transpl; 2008 Feb; 14(2):173-80. PubMed ID: 18236391
[TBL] [Abstract][Full Text] [Related]
14. Clinical use of FK 506 in liver transplantation.
Klintmalm GB
Transplant Proc; 1996 Apr; 28(2):974-6. PubMed ID: 8623484
[TBL] [Abstract][Full Text] [Related]
15. Therapy with FK 506 in pediatric liver recipients.
Rosh JR; Schwersenz AH; Schwartz M; Moran V; Leleiko N; LeLeiko VM; Miller CM
Transplant Proc; 1994 Feb; 26(1):152-3. PubMed ID: 7509091
[No Abstract] [Full Text] [Related]
16. Long-term evaluation of cyclosporine and tacrolimus based immunosuppression in pediatric liver transplantation.
Hasenbein W; Albani J; Englert C; Spehr A; Grabhorn E; Kemper MJ; Burdelski M; Ganschow R
Pediatr Transplant; 2006 Dec; 10(8):938-42. PubMed ID: 17096762
[TBL] [Abstract][Full Text] [Related]
17. FK 506 rescue therapy: early conversion improves efficacy.
Woodle ES; Perdrizet GA; So S; Jendrisak MD; White HM; Marsh JW
Transplant Proc; 1993 Apr; 25(2):1990-1. PubMed ID: 7682359
[No Abstract] [Full Text] [Related]
18. Severe neurotoxicity after liver transplantation: association between FK 506 therapy and hepatitis C virus disease.
Mueller AR; Platz KP; Christe W; Bechstein WO; Blumhardt G; Neuhaus P
Transplant Proc; 1994 Dec; 26(6):3131-2. PubMed ID: 7527951
[No Abstract] [Full Text] [Related]
19. Causes of death following liver transplantation in FK 506- and cyclosporine-treated patients.
Platz KP; Mueller AR; Bechstein WO; Blumhardt G; Neuhaus P
Transplant Proc; 1994 Dec; 26(6):3133-4. PubMed ID: 7527952
[No Abstract] [Full Text] [Related]
20. Tacrolimus (FK 506) therapy is associated with a significant reduction in immunosuppressive treatment failures following primary liver transplantation.
Bechstein WO; Neuhaus P; McMaster P; Calne R; Pichlmayr R; Otto G; Williams R; Ericzon BG; Bismuth H
Transplant Proc; 1996 Apr; 28(2):1008-10. PubMed ID: 8623211
[No Abstract] [Full Text] [Related]
[Next] [New Search]
